Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Total Liabilities (2018 - 2025)

Revolution Medicines (RVMD) has 7 years of Total Liabilities data on record, last reported at $723.2 million in Q4 2025.

  • For Q4 2025, Total Liabilities rose 146.75% year-over-year to $723.2 million; the TTM value through Dec 2025 reached $723.2 million, up 146.75%, while the annual FY2025 figure was $723.2 million, 146.75% up from the prior year.
  • Total Liabilities reached $723.2 million in Q4 2025 per RVMD's latest filing, up from $655.0 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $723.2 million in Q4 2025 and bottomed at $89.0 million in Q2 2021.
  • Average Total Liabilities over 5 years is $234.3 million, with a median of $145.6 million recorded in 2022.
  • Peak YoY movement for Total Liabilities: fell 8.16% in 2023, then soared 233.01% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $135.4 million in 2021, then decreased by 6.41% to $126.7 million in 2022, then skyrocketed by 85.82% to $235.5 million in 2023, then grew by 24.45% to $293.1 million in 2024, then skyrocketed by 146.75% to $723.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Liabilities were $723.2 million in Q4 2025, $655.0 million in Q3 2025, and $564.2 million in Q2 2025.